Advertisement

Chikungunya Virus-Associated Disease

Infection and Arthritis (K Winthrop, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Infections and Arthritis

Abstract

Purpose of Review

Chikungunya virus (CHIKV) infection has become increasingly prevalent in the last decade not only across the southern hemisphere but also, because of a recently documented viral mutation, in southern Europe and the USA. With the global spread of CHIKV infection, practitioners should know its epidemiology, pathophysiology and clinical features.

Recent Findings

The acute phase of CHIKV disease is characterised by a fever–arthralgia–rash syndrome. Chronic rheumatic manifestations can persist for months to years with very variable clinical presentations. Some cases mimic inflammatory rheumatism such as rheumatoid arthritis. Several risk factors for persistent joint pain, notably older age, have been identified in cohort studies.

Summary

Despite a low mortality rate with CHIKV infection, the rate of disability with chronic joint symptoms is high, and effective treatments are lacking. Current research is focusing on the development of vaccines and antiviral drugs, and data on treatment of CHIKV-induced chronic arthritis are needed.

Keywords

Chikungunya Infection-associated arthritis Arbovirus 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Ross RW. The Newala epidemic. III. The virus: isolation, pathogenic properties and relationship to the epidemic. J Hyg (Lond). 1956;54:177–91.CrossRefGoogle Scholar
  2. 2.
    •• Silva LA, Dermody TS. Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies. J Clin Invest. 2017;127:737–49. This is a recent review describing epidemiology and pathogenesis of CHIKV CrossRefPubMedGoogle Scholar
  3. 3.
    Renault P, Josseran L, Pierre V. Chikungunya-related fatality rates, Mauritius, India, and Reunion Island. Emerg Infect Dis. 2008;14:1327.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Carey DE. Chikungunya and dengue: a case of mistaken identity? J Hist Med Allied Sci. 1971;26:243–62.CrossRefPubMedGoogle Scholar
  5. 5.
    Halstead SB. Reappearance of chikungunya, formerly called dengue, in the Americas. Emerg Infect Dis. 2015;21:557–61.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    •• Weaver SC, Lecuit M. Chikungunya virus and the global spread of a mosquito-borne disease. N Engl J Med. 2015;372:1231–9. This paper presents recent data on clinical manifestations of CHIKV infection as well as on its epidemiology and treatment CrossRefPubMedGoogle Scholar
  7. 7.
    Volk SM, Chen R, Tsetsarkin KA, et al. Genome-scale phylogenetic analyses of chikungunya virus reveal independent emergences of recent epidemics and various evolutionary rates. J Virol. 2010;84:6497–504.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Lemant J, Boisson V, Winer A, et al. Serious acute chikungunya virus infection requiring intensive care during the Reunion Island outbreak in 2005-2006. Crit Care Med. 2008;36:2536–41.CrossRefPubMedGoogle Scholar
  9. 9.
    Rezza G, Nicoletti L, Angelini R, et al. Infection with chikungunya virus in Italy: an outbreak in a temperate region. Lancet Lond Engl. 2007;370:1840–6.CrossRefGoogle Scholar
  10. 10.
    Grandadam M, Caro V, Plumet S, et al. Chikungunya virus, southeastern France. Emerg Infect Dis. 2011;17:910–3.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Yactayo S, Staples JE, Millot V, et al. Epidemiology of chikungunya in the Americas. J Infect Dis. 2016;214:S441–5.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    • Simon F, Javelle E, Cabie A, et al. French guidelines for the management of chikungunya (acute and persistent presentations). November 2014. Med Mal Infect. 2015;45:243–63. In this article, recent guidelines for clinical management of CHIKV infection are presented. CrossRefPubMedGoogle Scholar
  13. 13.
    Amraoui F, Failloux A-B. Chikungunya: an unexpected emergence in Europe. Curr. Opin. Virol. 2016;21:146–50.CrossRefPubMedGoogle Scholar
  14. 14.
    Staples JE, Breiman RF, Powers AM. Chikungunya fever: an epidemiological review of a re-emerging infectious disease. Clin Infect Dis Off Publ Infect Dis Soc Am. 2009;49:942–8.CrossRefGoogle Scholar
  15. 15.
    Khoury VJ, Camilo PR. Chikungunya virus (CHIKV): what can be expected after the acute phase? Reumatol Clin. 2016;12:1–3.CrossRefPubMedGoogle Scholar
  16. 16.
    Brouard C, Bernillon P, Quatresous I, et al. Estimated risk of chikungunya viremic blood donation during an epidemic on Reunion Island in the Indian Ocean, 2005 to 2007. Transfusion (Paris). 2008;48:1333–41.CrossRefGoogle Scholar
  17. 17.
    Ali Ou Alla S, Combe B. Arthritis after infection with chikungunya virus. Best Pract Res Clin Rheumatol. 2011;25:337–46.CrossRefPubMedGoogle Scholar
  18. 18.
    Economopoulou A, Dominguez M, Helynck B, et al. Atypical chikungunya virus infections: clinical manifestations, mortality and risk factors for severe disease during the 2005-2006 outbreak on Réunion. Epidemiol Infect. 2009;137:534–41.CrossRefPubMedGoogle Scholar
  19. 19.
    Waymouth HE, Zoutman DE, Towheed TE. Chikungunya-related arthritis: case report and review of the literature. Semin Arthritis Rheum. 2013;43:273–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Gérardin P, Fianu A, Michault A, et al. Predictors of chikungunya rheumatism: a prognostic survey ancillary to the TELECHIK cohort study. Arthritis Res Ther. 2013;15:R9.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Chopra A, Anuradha V, Lagoo-Joshi V, et al. Chikungunya virus aches and pains: an emerging challenge. Arthritis Rheum. 2008;58:2921–2.CrossRefPubMedGoogle Scholar
  22. 22.
    Hoarau J-J, Jaffar Bandjee M-C, Krejbich Trotot P, et al. Persistent chronic inflammation and infection by chikungunya arthritogenic alphavirus in spite of a robust host immune response. J Immunol Baltim Md 1950. 2010;184:5914–27.Google Scholar
  23. 23.
    Tanay A. Chikungunya virus and autoimmunity. Curr Opin Rheumatol. 2017;29:389–93.CrossRefPubMedGoogle Scholar
  24. 24.
    Bouquillard E, Fianu A, Bangilo M, et al. Rheumatic manifestations associated with chikungunya virus infection: a study of 307 patients with 32-month follow-up (RHUMATOCHIK study). Joint Bone Spine. 2017.  https://doi.org/10.1016/j.jbspin.2017.01.014.
  25. 25.
    Rodríguez-Morales AJ, Cardona-Ospina JA, Fernanda Urbano-Garzón S, et al. Prevalence of post-chikungunya infection chronic inflammatory arthritis: a systematic review and meta-analysis. Arthritis Care Res. 2016;68:1849–58.CrossRefGoogle Scholar
  26. 26.
    Bouquillard E, Combe B. A report of 21 cases of rheumatoid arthritis following chikungunya fever. A mean follow-up of two years. Jt Bone Spine Rev Rhum. 2009;76:654–7.CrossRefGoogle Scholar
  27. 27.
    Rahim AA, Thekkekara RJ, Bina T, et al. Disability with persistent pain following an epidemic of chikungunya in rural South India. J Rheumatol. 2016;43:440–4.CrossRefPubMedGoogle Scholar
  28. 28.
    Ng KW, Chow A, Win MK, et al. Clinical features and epidemiology of chikungunya infection in Singapore. Singap Med J. 2009;50:785–90.Google Scholar
  29. 29.
    Lee VJ, Chow A, Zheng X, et al. Simple clinical and laboratory predictors of chikungunya versus dengue infections in adults. PLoS Negl Trop Dis. 2012;6:e1786.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Mohd Zim MA, Sam IC, Omar SF, et al. Chikungunya infection in Malaysia: comparison with dengue infection in adults and predictors of persistent arthralgia. J Clin Virol. 2013;56:141–5.CrossRefPubMedGoogle Scholar
  31. 31.
    Morrison JG. Chikungunya fever. Int J Dermatol. 1979;18:628–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Sam I-C, AbuBakar S. Chikungunya virus infection. Med J Malaysia. 2006;61:264–9.PubMedGoogle Scholar
  33. 33.
    Cavrini F, Gaibani P, Pierro AM, et al. Chikungunya: an emerging and spreading arthropod-borne viral disease. J Infect Dev Ctries. 2009;3:744–52.PubMedGoogle Scholar
  34. 34.
    Schilte C, Staikowsky F, Staikovsky F, et al. Chikungunya virus-associated long-term arthralgia: a 36-month prospective longitudinal study. PLoS Negl Trop Dis. 2013;7:e2137.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Win MK, Chow A, Dimatatac F, et al. Chikungunya fever in Singapore: acute clinical and laboratory features, and factors associated with persistent arthralgia. J Clin Virol. 2010;49:111–4.CrossRefPubMedGoogle Scholar
  36. 36.
    Gasque P, Bandjee MCJ, Reyes MM, et al. Chikungunya pathogenesis: from the clinics to the bench. J Infect Dis. 2016;214:S446–8.CrossRefPubMedGoogle Scholar
  37. 37.
    •• Burt FJ, Chen W, Miner JJ, et al. Chikungunya virus: an update on the biology and pathogenesis of this emerging pathogen. Lancet Infect Dis. 2017;17:e107–17. This paper provides recent pathogenesis data. CrossRefPubMedGoogle Scholar
  38. 38.
    Teng T-S, Kam Y-W, Lee B, et al. A systematic meta-analysis of immune signatures in patients with acute chikungunya virus infection. J Infect Dis. 2015;211:1925–35.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Miner JJ, Aw Yeang HX, Fox JM, et al. Chikungunya viral arthritis in the United States: a mimic of seronegative rheumatoid arthritis. Arthritis Rheumatol. Hoboken NJ. 2015;67:1214–20.CrossRefGoogle Scholar
  40. 40.
    Teo T-H, Lum F-M, Claser C, et al. A pathogenic role for CD4+ T cells during chikungunya virus infection in mice. J. Immunol. Baltim. Md 1950. 2013;190:259–69.Google Scholar
  41. 41.
    Labadie K, Larcher T, Joubert C, et al. Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages. J Clin Invest. 2010;120:894–906.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Burt F, Chen W, Mahalingam S. Chikungunya virus and arthritic disease. Lancet Infect Dis. 2014;14:789–90.CrossRefPubMedGoogle Scholar
  43. 43.
    Nakaya HI, Gardner J, Poo Y-S, et al. Gene profiling of chikungunya virus arthritis in a mouse model reveals significant overlap with rheumatoid arthritis. Arthritis Rheum. 2012;64:3553–63.CrossRefPubMedGoogle Scholar
  44. 44.
    Differentiating chikungunya from dengue: a clinical challenge [Internet]. Medscape. [cited 2017 Jul 25]. Available from: http://www.medscape.com/viewarticle/831523.
  45. 45.
    Krutikov M, Manson J. Chikungunya virus infection: an update on joint manifestations and management. Rambam Maimonides Med J. 2016;7Google Scholar
  46. 46.
    Ganu MA, Ganu AS. Post-chikungunya chronic arthritis—our experience with DMARDs over two year follow up. J Assoc Physicians India. 2011;59:83–6.PubMedGoogle Scholar
  47. 47.
    Organization WH, Asia RO for S-E. Guidelines on clinical management of chikungunya fever. 2008 [cited 2017 Jul 30]; Available from: http://www.who.int/iris/handle/10665/205178.
  48. 48.
    De Lamballerie X, Boisson V, Reynier J-C, et al. On chikungunya acute infection and chloroquine treatment. Vector Borne Zoonotic Dis Larchmt N. 2008;8:837–9.CrossRefGoogle Scholar
  49. 49.
    Martí-Carvajal A, Ramon-Pardo P, Javelle E, et al. Interventions for treating patients with chikungunya virus infection-related rheumatic and musculoskeletal disorders: a systematic review. PLoS One. 2017;12:e0179028.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Chopra A, Saluja M, Venugopalan A. Effectiveness of chloroquine and inflammatory cytokine response in patients with early persistent musculoskeletal pain and arthritis following chikungunya virus infection. Arthritis Rheumatol Hoboken NJ. 2014;66:319–26.CrossRefGoogle Scholar
  51. 51.
    Javelle E, Ribera A, Degasne I, et al. Specific management of post-chikungunya rheumatic disorders: a retrospective study of 159 cases in Reunion Island from 2006-2012. PLoS Negl Trop Dis. 2015;9:e0003603.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Miner JJ, Cook LE, Hong JP, et al. Therapy with CTLA4-Ig and an antiviral monoclonal antibody controls chikungunya virus arthritis. Sci Transl Med. 2017;9Google Scholar
  53. 53.
    Abdelnabi R, Neyts J, Delang L. Towards antivirals against chikungunya virus. Antivir Res. 2015;121:59–68.CrossRefPubMedGoogle Scholar
  54. 54.
    Abdelnabi R, Neyts J, Delang L. Chikungunya virus infections: time to act, time to treat. Curr Opin Virol. 2017;24:25–30.CrossRefPubMedGoogle Scholar
  55. 55.
    Smalley C, Erasmus JH, Chesson CB, et al. Status of research and development of vaccines for chikungunya. Vaccine. 2016;34:2976–81.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  1. 1.Rheumatology Department, Lapeyronie HospitalMontpellier UniversityMontpellierFrance

Personalised recommendations